
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Heat Biologics, Inc is a biotechnology business with stocks listed in the US. Heat Biologics shares (HTBX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$7.91 – a decrease of -INF% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | US$3.22 - US$30.1 |
---|---|
50-day moving average | US$8.2609 |
200-day moving average | US$7.9613 |
Target price | US$29.25 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | US$-0.654 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $7.91 on 2021-02-25
1 week (2021-02-26) | N/A |
---|---|
1 month (2021-02-05) | N/A |
3 months (2020-12-05) | N/A |
6 months (2020-09-05) | N/A |
1 year (2020-03-05) | N/A |
---|---|
2 years (2019-03-05) | N/A |
3 years (2018-03-05) | N/A |
5 years (2016-03-05) | N/A |
Revenue TTM | US$4.3 million |
---|---|
Gross profit TTM | US$-9,964,500 |
Return on assets TTM | -17.49% |
Return on equity TTM | -33.73% |
Profit margin | 0% |
Book value | 5.418 |
Market capitalisation | US$179.7 million |
TTM: trailing 12 months
There are currently 2.0 million Heat Biologics shares held short by investors – that's known as Heat Biologics's "short interest". This figure is 6.2% up from 1.9 million last month.
There are a few different ways that this level of interest in shorting Heat Biologics shares can be evaluated.
Heat Biologics's "short interest ratio" (SIR) is the quantity of Heat Biologics shares currently shorted divided by the average quantity of Heat Biologics shares traded daily (recently around 5.1 million). Heat Biologics's SIR currently stands at 0.4. In other words for every 100,000 Heat Biologics shares traded daily on the market, roughly 400 shares are currently held short.
However Heat Biologics's short interest can also be evaluated against the total number of Heat Biologics shares, or, against the total number of tradable Heat Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Heat Biologics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Heat Biologics shares in existence, roughly 90 shares are currently held short) or 0.0915% of the tradable shares (for every 100,000 tradable Heat Biologics shares, roughly 92 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Heat Biologics.
Find out more about how you can short Heat Biologics stock.
We're not expecting Heat Biologics to pay a dividend over the next 12 months.
Heat Biologics's shares were split on a 1:7 basis on 11 December 2020. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Heat Biologics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Heat Biologics shares which in turn could have impacted Heat Biologics's share price.
Over the last 12 months, Heat Biologics's shares have ranged in value from as little as US$3.22 up to US$30.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Heat Biologics's is 0.166. This would suggest that Heat Biologics's shares are less volatile than average (for this exchange).
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company's preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.
Steps to owning and managing Liberty Financial Group shares.
Steps to owning and managing Cettire shares.
Steps to owning and managing BHP Group shares.
Steps to owning and managing Fisher & Paykel Healthcare Corp Ltd shares.
From Membership Rewards Points to savings on first and business class flights, this charge card is packed with features to help you manage business spending.
From the best sheets for summer to the most luxurious threads, these are the 7 best bed sheets you can get in Australia right now.
Steps to owning and managing MicroStrategy shares.
Everything we know about the Superhero IPO, plus information on how to buy in.
Everything we know about the Coinbase IPO, plus information on how to buy in.
Everything we know about the Databricks IPO, plus information on how to buy in.